FibroBiologics Sets $8 Reference Price for Today’s Nasdaq Direct Listing

FibroBiologics announced that trading of its stock began today in a direct listing on the Nasdaq under the ticker symbol FBLG. Thw reference price was set at $8 a share.

Houston-based FibroBiologics is a clinical-stage biotechnology company focused on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials.

The company intends to offer 4,806,226 shares in the listing.

A private placement was completed over a year ago at the equivalent of $6.76 per share, according to the prospectus.

FibroBiologics holds 150+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, wound healing, reversing organ involution and cancer. Read more.

Related Posts
Read More

Some Investors Find Stability in SPACs

Known on Wall Street as SPAC arbitrage, the trade has become turbocharged of late—thanks in equal parts to the day-trader-fueled craze for SPACs that materialized late last year and the more-recent slump in SPAC demand.
Read More

June SPAC Merger Vote Calendar

Benzinga's montly calendar of upcoming SPAC merger votes has just been published. Several of the recently completed SPAC mergers have seen shares trade higher going into the merger vote, as well as shortly after completing the ticker and company name changeover in the de-SPAC process.